A landmark RNA profiling effort split canine splenic hemangiosarcoma into three molecularly actionable subtypes, showing that tumors arising in the same dog can be biologically distinct at the gene-expression level. The study also points to subtype-specific implications for therapy and prognosis in veterinary oncology. The work demonstrates the feasibility of using transcriptomic signatures to overcome the historical one-size-fits-all approach in aggressive canine cancers. For translational audiences, the study supports comparative oncology as a route to better stratification—where molecular classification can guide treatment decisions even outside human trials. The near-term impact will depend on how quickly subtype markers can be implemented in routine diagnostics and whether subtype mapping correlates with measurable response differences.